Distinguished in Neurotoxicity Syndromes

Dr. Robert A. Hauser

Neurology
University Medical Service Association Inc
13330 Usf Laurel Dr, 
Tampa, FL 
Accepting New Patients
43 Years of Experience
Distinguished in Neurotoxicity Syndromes
University Medical Service Association Inc
13330 Usf Laurel Dr, 
Tampa, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Hauser is a Neurologist in Tampa, Florida. Dr. Hauser has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Neurotoxicity Syndromes. His top areas of expertise are Parkinson's Disease, Movement Disorders, Drug Induced Dyskinesia, and Tardive Dyskinesia. Dr. Hauser is currently accepting new patients.

His clinical research consists of co-authoring 203 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 18 articles in the study of Neurotoxicity Syndromes.

Graduate Year
1982
Specialties
Neurology
Licenses
Psychiatry & Neurology in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

UNIVERSITY MEDICAL SERVICE ASSOCIATION INC
13330 Usf Laurel Dr, Tampa, FL 33612
Other Locations
UNIVERSITY MEDICAL SERVICE ASSOCIATION INC
4001 E Fletcher Ave, Tampa, FL 33613
UNIVERSITY MEDICAL SERVICE ASSOCIATION INC
12901 Bruce B Downs Blvd, Tampa, FL 33612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Enrollment Status: Active_not_recruiting
Publish Date: September 20, 2024
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: CVN424
Study Phase: Phase 2
A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period
A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period
Enrollment Status: Terminated
Publish Date: March 19, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 2
A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.
A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.
Enrollment Status: Withdrawn
Publish Date: March 01, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 1
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia
Enrollment Status: Completed
Publish Date: February 14, 2024
Intervention Type: Drug
Study Drug: ABP-450
Study Phase: Phase 2
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
The Parkinson's Progression Markers Initiative (PPMI)
The Parkinson's Progression Markers Initiative (PPMI)
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: DaTscan
Study Phase: Phase 2
RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy
RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy
Enrollment Status: Completed
Publish Date: August 23, 2023
Intervention Type: Drug
Study Drug: Droxidopa
Study Phase: Phase 4
Parkinson's Foundation Quality Improvement Initiative
Parkinson's Foundation Quality Improvement Initiative
Enrollment Status: Completed
Publish Date: July 14, 2023
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
Enrollment Status: Terminated
Publish Date: February 28, 2022
Intervention Type: Drug
Study Drug: BIIB054
Study Phase: Phase 2
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants With Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants With Parkinson's Disease
Enrollment Status: Completed
Publish Date: July 22, 2020
Intervention Type: Drug
Study Phase: Phase 2
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
Enrollment Status: Completed
Publish Date: January 09, 2020
Intervention Type: Drug, Other
Study Phase: Phase 2
View 13 Less Clinical Trials

463 Total Publications

Procedural tricuspid valve damage associated with leadless pacemakers.
Procedural tricuspid valve damage associated with leadless pacemakers.
Journal: Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
Published: April 30, 2025
Similar Doctors
Advanced in Neurotoxicity Syndromes
Dr. Bhavik L. Gedia
Neurology
Advanced in Neurotoxicity Syndromes
Dr. Bhavik L. Gedia
Neurology

Baycare Medical Group, Inc.

3003 W Dr Martin Luther King Jr Blvd, 
Tampa, FL 
 (7.4 miles away)
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Bhavik Gedia is a Neurologist in Tampa, Florida. Dr. Gedia is rated as an Advanced provider by MediFind in the treatment of Neurotoxicity Syndromes. His top areas of expertise are Seizures, Neurotoxicity Syndromes, Stroke, Generalized Tonic-Clonic Seizure, and Gastrostomy. Dr. Gedia is currently accepting new patients.

Advanced in Neurotoxicity Syndromes
Dr. Rafael M. Rodriguez
Neurology
Advanced in Neurotoxicity Syndromes
Dr. Rafael M. Rodriguez
Neurology

Neurophysiology Center P.A.

401 N Parson Ave, Suite 105, 
Brandon, FL 
 (11.8 miles away)
813-653-2775
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Rafael Rodriguez is a Neurologist in Brandon, Florida. Dr. Rodriguez is rated as a Distinguished provider by MediFind in the treatment of Neurotoxicity Syndromes. His top areas of expertise are Seizures, Trigeminal Neuralgia, Familial Neurocardiogenic Syncope, Cerebellar Degeneration, and Gastrostomy. Dr. Rodriguez is currently accepting new patients.

Advanced in Neurotoxicity Syndromes
Dr. Zahid I. Choudary
Neurology
Advanced in Neurotoxicity Syndromes
Dr. Zahid I. Choudary
Neurology
11922 Boyette Rd, 
Riverview, FL 
 (16.4 miles away)
813-337-6178
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Zahid Choudary is a Neurologist in Riverview, Florida. Dr. Choudary is rated as an Advanced provider by MediFind in the treatment of Neurotoxicity Syndromes. His top areas of expertise are Neurotoxicity Syndromes, Stroke, Familial Neurocardiogenic Syncope, and Seizures. Dr. Choudary is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hauser's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile